Healome Therapeutics is developing a proprietary eye drop technology that enhances drug retention, lubrication, and protection for patients with ocular surface diseases and injuries. Their approach aims to improve therapeutic outcomes and quality of life by reformulating existing ocular medications and creating novel treatments tailored to eye health challenges.
Funding
$206.9K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for ocular surface diseases and injuries often suffer from poor drug retention, inadequate lubrication, and insufficient protection of the affected area, leading to suboptimal therapeutic outcomes and reduced patient quality of life. Existing ocular medications may not effectively address the underlying causes of these conditions or promote efficient healing of damaged tissue.
Solution
Healome Therapeutics is developing a proprietary eye drop technology designed to enhance drug retention, lubrication, and protection for individuals with ocular surface diseases and injuries. Their approach involves engineering microenvironments through an eye drop matrix technology to improve the therapeutic effect of both existing and novel ocular medicines. By reformulating existing medications and creating new treatments, Healome aims to improve clinical outcomes and quality of life through safer, simpler, and more scalable approaches to eye care. The technology seeks to address the root causes of ocular surface conditions and promote the healing of damaged tissue.
Target Audience
Healome Therapeutics targets patients suffering from ocular surface diseases and injuries, as well as healthcare providers seeking more effective and practical treatments for these conditions.
Features
- Proprietary eye drop matrix technology for enhanced drug retention at the ocular surface
- Reformulation of existing ocular medications to improve therapeutic value
- Development of novel therapeutics targeting the underlying causes of ocular surface diseases
- Creation of microenvironments within eye drops to encourage healing of the eye
- Scalable approach to delivering advanced eye care